Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake of biosimilar monoclonal antibodies (MAbs) in oncology will drive robust sales of drugs within this class. The most notable near-term biosimilar targets for MAbs in oncology are Genentech/Roche's Herceptin and Rituxan/MabThera.

The new special report Biosimilars 2007-2017: Shifting Payer and Physician Opinion Increases the Hurdles to Uptake forecasts that sales of biosimilar Herceptin will approach blockbuster status in 2017 in Europe alone, and biosimilar Rituxan/MabThera will garner $940 million in sales by 2017 in the United States, France, Germany, Italy, Spain and the United Kingdom. Based on the success of branded Herceptin and Rituxan/MabThera, near-term opportunity exists for drug manufacturers investing in the development of biosimilar MAbs in oncology. The report finds that oncologists will be among the most aggressive users of biosimilar drugs, and the high turnover of oncology patients will accelerate growth and penetration within the relatively un-crowded biosimilar MAb market.

Although oncology will prove to be a robust market, the opportunity for biosimilars varies significantly by therapeutic area, according to the report. For example, owing to an increasingly cautious attitude among neurologists regarding safety and efficacy associated with the use of biosimilars in chronic diseases like multiple sclerosis, the expectations for biosimilar interferon-betas in neurology remain tempered. Additionally, the emergence of novel multiple sclerosis therapies will constrain interferon-beta use over the long-term; prior to biosimilar entry, forecasted sales of interferon-betas in the United States and European Union will fall to $2.3 billion in 2017-a significant decline from their peak sales of more than $4.7 billion in 2010.

"Despite the success of biosimilars in some areas such as cancer treatment, the launches of biosimilar interferon-betas for neurology in Europe in 2010 and in the U.S. in 2014, will not generate significant uptake of these agents," said Nicole Westphal, Ph.D., analyst at Decision Resources. "Given the high cost of clinical development, the conservative prescribing habits of neurologists, and the declining use of interferon-betas by 2017, biosimilar developers may want to explore other classes of biologics in which to invest their research and development funds."

About the Report

Biosimilars 2007-2017: Shifting Payer and Physician Opinion Increases the Hurdles to Uptake covers 18 key biologic brands from seven biologic classes and includes surveys of 402 U.S. and European physicians and 40 MCO pharmacy directors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                    Decision Resources, Inc.   Christopher Comfort                   Elizabeth Marshall   781-296-2597                          781-296-2563   ccomfort@dresources.com               emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

Contact: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

MRI of the Breast Continues to Show Double Digit Growth In 2008

View Now